Preclinical Data

JAK Pathway | Explore JAK signaling, one pathway involved in cytokine-mediated cellular processes

Preclinical Data

JAK Signaling in Disease | Some key disease-related cytokines that signal through the JAK pathway

Preclinical Data

Preclinical Data | Cytokine inhibition profiles of Pfizer JAK inhibitors that informed clinical research efforts

Preclinical Data

Pfizer I&I Pipeline | Scientific innovation and discovery in Inflammation & Immunology1,a

Pfizer I&I Pipeline | Scientific innovation and discovery in JAK inhibitors1,a

JAK PATHWAY JAK PATHWAY
Select to view pathway changes caused by JAK inhibitors
Examples of cytokines that signal through the JAK pathway2-4
Cytokine
type
JAK
enzyme
pairings
Cellular
processes
Gamma-chain family cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21)
JAK PATHWAY
Inflammation, growth/ maturation of immune cells, differentiation of T cells and natural killer cells
Type I IFNs (IFN-α/β) IL-10 family (IL-10, IL-20, IL-22)
JAK PATHWAY
Antiviral, inflammation, antitumor activity
IL-6, IL-11, IL-13, IL-27, IL-31, IL-35, OSM, LIF
JAK PATHWAY
Naive T-cell differentiation, T-cell regulation, inflammation
Type II IFN (IFN-γ), TSLP
JAK PATHWAY
Antiviral, inflammation, antimycobacterial activity, differentiation of T cells
IL-12, IL-23
JAK PATHWAY
Innate immunity, differentiation of T cells, inflammation
Select a
therapeutic
area
DERMATOLOGY1-11,a
JAK PATHWAY JAK PATHWAY
RHEUMATOLOGY1-17,a
JAK PATHWAY JAK PATHWAY
GASTROENTEROLOGY1-5,a
JAK PATHWAY JAK PATHWAY
DERMATOLOGY1-11,a
JAK PATHWAY JAK PATHWAY

Some of these cytokines have been observed to play a role in certain disease states. Select a tappable cytokine to learn more.

JAK PATHWAY
ALOPECIA
AREATA
JAK PATHWAY
VITILIGO
JAK PATHWAY
ATOPIC
DERMATITIS
JAK PATHWAY
HIDRADENITIS
SUPPURATIVA
RHEUMATOLOGY1-17,a
JAK PATHWAY JAK PATHWAY
GASTROENTEROLOGY1-5,a
JAK PATHWAY JAK PATHWAY

Some of these cytokines have been observed to play a role in certain disease states. Select a clickable cytokine on the left to learn more.

Slider Plots blue Slider Plots orange Slider Plots green Slider Plots red Slider Plots
Select up to 4 compounds below to view the different cytokine inhibition profiles.1-4
Compound
Color
PF-06826647 TYK2 inhibitor
Ritlecitinib (PF-06651600) JAK3/TEC inhibitor
Brepocitinib (PF-06700841) TYK2/JAK1 inhibitor
Abrocitinib (PF-04965842) JAK1 inhibitor
Cytokine inhibition profiles are based on preclinical data and are not a representation of clinical efficacy.

About the data

These profiles represent the ability of a compound to inhibit a specific biological or biochemical function in vitro. Whole blood assays were used to assess JAK inhibition by stimulating cells with cytokines and measuring the level of STAT phosphorylation.4,5 It is important to note that these plots may vary between assays depending on the parameters of the assay, such as the dose of compound used or the cytokines measured.6,7

Additionally, many factors other than preclinical selectivity are relevant to the clinical profile of a JAK inhibitor.6,8 These additional factors also influence the effectiveness and safety of a JAK inhibitor in the clinical setting.6-8

Explore JAK inhibitors in the Pfizer I&I pipeline

Swipe left or right to view the diferent phases.

Dermatology

Over 5 compounds under investigation in multiple dermatology disease states
DISEASE STATE

alopecia areata

VITILIGO

atopic dermatitis

plaque psoriasis

STASIS DERMATITIS

HIDRADENITIS SUPPURATIVA

PHASE 1
PHASE 2
Completed
TYK2/
JAK1b,c

INHIBITOR

Active, not recruiting
JAK3/
TEC

INHIBITOR

Active, not recruiting
TYK2/
JAK1c

INHIBITOR

Recruiting
TYK2/
JAK1f

INHIBITOR

Recruiting
TYK2

INHIBITOR

Recruiting
TYK2/
JAK1f

INHIBITOR

More info coming soon
PDE4g

INHIBITOR

Recruiting
IRAK4

INHIBITOR

Recruiting
TYK2

INHIBITOR

Recruiting
TYK2/
JAK1c

INHIBITOR

PHASE 3
Recruiting
JAK3/
TECd,e

INHIBITOR

Recruiting
PDE4g

INHIBITOR

Recruiting
JAK1e

INHIBITOR

Gastroenterology

Over 4 compounds under investigation in multiple gastroenterology disease states
DISEASE STATE

crohn's disease

ulcerative colitis

NAFLD/NASHi

PHASE 1
Completed
DGAT2

INHIBITOR

PHASE 2
Recruiting
JAK3/
TEC

INHIBITOR

Recruiting
TYK2/
JAK1c

INHIBITOR

Recruiting
IL-10h

IMMUNO-
CYTOKINE

Recruiting
TNFSF15

BLOCKER

Recruiting
TYK2

INHIBITOR

Recruiting
JAK3/
TEC

INHIBITOR

Recruiting
TYK2/
JAK1c

INHIBITOR

Completed
ACCi+
DGAT2

INHIBITOR

Completed
ACCj

INHIBITOR

Completed
KHK

INHIBITOR

PHASE 3

Rheumatology

Over 6 compounds under investigation in multiple rheumatology disease states
DISEASE STATE

Lupus

PSORIATIC ARTHRITIS

Rheumatoid arthritis

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

JUVINILE IDIOPATHIC ARTHRITIS

PHASE 1
Recruiting
Chemokine

INHIBITOR

PHASE 2
More info coming soon
IFNB1

BLOCKER

Recruiting
TYK2/
JAK1c

INHIBITOR

Active, not recruiting
TYK2/
JAK1c

INHIBITOR

No information available
IL-10k

IMMUNO-
CYTOKINE

Completed
IRAK4

INHIBITOR

Completed
JAK3/
TEC

INHIBITOR

PHASE 3
Recruiting
JAK1/
JAK3

INHIBITOR

Recruiting
JAK1/
JAK3l

INHIBITOR

ADVANCING RESEARCH WITH THE GOAL OF LIFE-CHANGING IMPACT

Are you a healthcare professional?

The information on this site is intended for U.S. healthcare professionals.